Ryan Massa

946 total citations · 1 hit paper
16 papers, 245 citations indexed

About

Ryan Massa is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Ryan Massa has authored 16 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 3 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in Ryan Massa's work include Cancer Immunotherapy and Biomarkers (7 papers), Pancreatic and Hepatic Oncology Research (5 papers) and CAR-T cell therapy research (3 papers). Ryan Massa is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Pancreatic and Hepatic Oncology Research (5 papers) and CAR-T cell therapy research (3 papers). Ryan Massa collaborates with scholars based in United States. Ryan Massa's co-authors include Ursina Teitelbaum, Kim A. Reiss, Mark H. O’Hara, Charles Schneider, Thomas B. Karasic, Rashmi Tondon, Susan M. Domchek, Robert H. Vonderheide, Rosemarie Mick and Tullia C. Bruno and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ryan Massa

15 papers receiving 241 citations

Hit Papers

Blockade of LAG-3 and PD-1 leads to co-expression of cyto... 2024 2026 2025 2024 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
    2024 75 citations Anthony R. Cillo, Carly Cardello et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan Massa United States 6 176 72 66 43 35 16 245
Muhammad Adnan Khattak Australia 9 185 1.1× 101 1.4× 77 1.2× 37 0.9× 21 0.6× 33 264
Sanjeev Deva New Zealand 9 179 1.0× 64 0.9× 64 1.0× 29 0.7× 60 1.7× 37 249
Vanesa de Luque Spain 3 255 1.4× 158 2.2× 69 1.0× 25 0.6× 38 1.1× 3 336
Ya-Ching Hsieh United Kingdom 9 90 0.5× 76 1.1× 105 1.6× 40 0.9× 33 0.9× 12 268
Mei Xie China 11 100 0.6× 41 0.6× 93 1.4× 65 1.5× 99 2.8× 28 251
Shaocheng Lyu China 8 130 0.7× 37 0.5× 79 1.2× 62 1.4× 61 1.7× 50 259
Yongxu Zhou China 7 116 0.7× 101 1.4× 127 1.9× 72 1.7× 26 0.7× 15 265
Ching-Shan Luo Taiwan 5 124 0.7× 51 0.7× 125 1.9× 56 1.3× 84 2.4× 8 296
Arezou Abbasi United States 6 166 0.9× 87 1.2× 32 0.5× 28 0.7× 33 0.9× 12 229
Yinyin Zhang China 8 71 0.4× 85 1.2× 101 1.5× 29 0.7× 18 0.5× 10 231

Countries citing papers authored by Ryan Massa

Since Specialization
Citations

This map shows the geographic impact of Ryan Massa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan Massa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan Massa more than expected).

Fields of papers citing papers by Ryan Massa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan Massa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan Massa. The network helps show where Ryan Massa may publish in the future.

Co-authorship network of co-authors of Ryan Massa

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan Massa. A scholar is included among the top collaborators of Ryan Massa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan Massa. Ryan Massa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Tuteja, Sony, Xingmei Wang, Donna Capozzi, et al.. (2025). Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial. JCO Precision Oncology. 9(9). e2500086–e2500086.
2.
Chapin, William J., Ryan Massa, & Jennifer R. Eads. (2024). Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers. 4(1). 207–218. 1 indexed citations
3.
4.
Cillo, Anthony R., Carly Cardello, Feng Shan, et al.. (2024). Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 187(16). 4373–4388.e15. 75 indexed citations breakdown →
5.
Harr, Margaret, Håkon Håkonarson, Jessica P. Marini, et al.. (2022). Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing. Frontiers in Oncology. 12. 859846–859846. 10 indexed citations
6.
Karasic, Thomas B., Timothy J. Brown, Charles Schneider, et al.. (2022). Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. The Oncologist. 27(9). 716–e689. 22 indexed citations
7.
Reiss, Kim A., Rosemarie Mick, Ursina Teitelbaum, et al.. (2022). Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. The Lancet Oncology. 23(8). 1009–1020. 93 indexed citations
8.
Teitelbaum, Ursina, Mark H. O’Hara, Charles Schneider, et al.. (2022). A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).. Journal of Clinical Oncology. 40(16_suppl). 4021–4021. 2 indexed citations
9.
Karapetyan, Lilit, Arivarasan Karunamurthy, Anthony R. Cillo, et al.. (2022). Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.. Journal of Clinical Oncology. 40(16_suppl). 9514–9514. 1 indexed citations
10.
Brown, Timothy J., Thomas B. Karasic, Charles Schneider, et al.. (2021). Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.. Journal of Clinical Oncology. 39(15_suppl). e15580–e15580. 3 indexed citations
11.
Wilcox, Nicholas S., Chantal Tapé, Leah Zuroff, et al.. (2021). Anemia in a young Guinean male. SHILAP Revista de lepidopterología. 9(8). e04593–e04593. 1 indexed citations
12.
Lau‐Min, Kelsey S., Nevena Damjanov, Ryan Massa, et al.. (2020). DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 40(11). 1108–1129. 19 indexed citations
13.
14.
15.
Massa, Ryan, Mark C. Sparrow, Lin Huang, et al.. (2018). Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL).. Journal of Clinical Oncology. 36(15_suppl). e21507–e21507. 2 indexed citations
16.
Terracciano, Chiara, S. Fiore, Viviana Versace, et al.. (2009). Relapsing aidp responsive to intravenous immunoglobulin in poems syndrome. Journal of the Peripheral Nervous System. 14. 144–144. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Muhammad Adnan Khattak Breakdown of academic impact, for papers by Sanjeev Deva Breakdown of academic impact, for papers by Vanesa de Luque Breakdown of academic impact, for papers by Ya-Ching Hsieh Breakdown of academic impact, for papers by Mei Xie Breakdown of academic impact, for papers by Shaocheng Lyu Breakdown of academic impact, for papers by Yongxu Zhou Breakdown of academic impact, for papers by Ching-Shan Luo Breakdown of academic impact, for papers by Arezou Abbasi Breakdown of academic impact, for papers by Yinyin Zhang
Rankless by CCL
2026